<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04528446</url>
  </required_header>
  <id_info>
    <org_study_id>AAAS0922</org_study_id>
    <secondary_id>R01DK119266</secondary_id>
    <nct_id>NCT04528446</nct_id>
  </id_info>
  <brief_title>The Impact of Glomerular Disorders on Bone Quality and Strength</brief_title>
  <acronym>BoneGN</acronym>
  <official_title>The Impact of Glomerular Disorders on Bone Quality and Strength</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to: (1) determine the impact of glomerular disease&#xD;
      on bone strength and (2) investigate the pathophysiologic underpinnings of impaired bone&#xD;
      strength in glomerular disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children and adults with glomerular disease have unique and potentially modifiable risk&#xD;
      factors for compromised bone health, but our current understanding of skeletal fragility in&#xD;
      glomerular disease is lacking. In the first large population-based cohort study, we recently&#xD;
      found that primary glomerular disease was independently associated with an increased risk of&#xD;
      incident fracture, and that hip fracture risk was &gt;2-fold greater in patients younger vs.&#xD;
      older than 40 years of age. Mechanisms that drive increased fracture risk in glomerular&#xD;
      disease are not clear but likely multifactorial. Our prior work demonstrated that glomerular&#xD;
      disease is associated with disturbances in vitamin D and mineral metabolism, in addition to&#xD;
      and exacerbated by reduced kidney function.&#xD;
&#xD;
      Patients with glomerular disease are also exposed to medications which may negatively impact&#xD;
      bone health, most notably high-dose and long-term glucocorticoid therapy. Identifying&#xD;
      modifiable factors that compromise bone strength will facilitate the development of&#xD;
      strategies to reduce fractures and other skeletal complications across the life course. The&#xD;
      proposed multi-center study will leverage the infrastructure of the NIH-funded Cure&#xD;
      Glomerulopathy (CureGN) prospective cohort study and the resources of two health systems with&#xD;
      expertise in state-of-the-art high-resolution bone imaging methods, to conduct the first&#xD;
      prospective, longitudinal study to assess determinants of impaired bone quality and strength&#xD;
      in glomerular disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2019</start_date>
  <completion_date type="Anticipated">December 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in radius bone strength (failure load)</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>HR-pQCT will be used to assess bone microarchitecture and generate micro-finite element analysis (µFEA)-based estimates of bone strength.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in tibia bone strength (failure load)</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>HR-pQCT will be used to assess bone microarchitecture and generate micro-finite element analysis (µFEA)-based estimates of bone strength.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radius mid-shaft failure load</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Measured with HR-pQCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tibia mid-shaft failure load</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Measured with HR-pQCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortical density of radius</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Measured with HR-pQCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortical density of tibia</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Measured with HR-pQCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortical thickness of radius</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Measured with HR-pQCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortical thickness of tibia</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Measured with HR-pQCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Areal bone mineral density (aBMD) at the hip</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Hip (total and femoral neck) is measured with dual-energy x-ray absorptiometry (DXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aBMD at forearm</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Forearm (one-third and ultradistal radius) is measured with DXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aBMD at lumbar spine</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Lumbar spine is measured with DXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone mineral content at the hip</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Hip (total and femoral neck) is measured with dual-energy x-ray absorptiometry (DXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone mineral content at forearm</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Forearm (one-third and ultradistal radius) is measured with DXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone mineral content at lumbar spine</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Lumbar spine is measured with DXA</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Glomerular Disease</condition>
  <condition>Bone Diseases, Metabolic</condition>
  <condition>Bone Fracture</condition>
  <arm_group>
    <arm_group_label>BoneGN participants</arm_group_label>
    <description>Participants who have already been recruited into the CureGN study, or meet its criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects</arm_group_label>
    <description>A reference population of healthy subjects who are age- sex- BMI-matched to the CureGN study participants.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Dual-energy X-ray absorptiometry</intervention_name>
    <description>DXA whole body, hip, spine, and radius at baseline, and 12-month visit.</description>
    <arm_group_label>BoneGN participants</arm_group_label>
    <other_name>Bone density</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT)</intervention_name>
    <description>HR-pQCT of the radius and tibia at baseline, and 12-month visit.</description>
    <arm_group_label>BoneGN participants</arm_group_label>
    <arm_group_label>Healthy subjects</arm_group_label>
    <other_name>HR-pQCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood draw and Urine collection</intervention_name>
    <description>The blood draw can be completed +/- 3 weeks from baseline or 12-month visit.</description>
    <arm_group_label>BoneGN participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>Questionnaires regarding fracture history, physical activity and dietary intake at baseline, and 12-month visit.</description>
    <arm_group_label>BoneGN participants</arm_group_label>
    <arm_group_label>Healthy subjects</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  Blood specimens (up to 50 ml or 3 ml/kg whichever is less) will be collected by&#xD;
           venipuncture by a trained phlebotomist, and aliquots of serum and plasma will be stored&#xD;
           at each visit for assays anticipated to be performed in one or two batches at the end of&#xD;
           the study and biobanking for future studies.&#xD;
&#xD;
        -  Participants will be asked to provide 20 ml urine sample for biobanking at the time of&#xD;
           the baseline and 12 month follow-up visits.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Prospective cohort study of 150 CureGN participants (100 adults/50 children) and 120 age-,&#xD;
        sex-, race-, and body mass index-matched healthy reference participants who will be&#xD;
        evaluated at baseline and 12 months.&#xD;
&#xD;
        The CureGN DCC at Arbor Research will identify CureGN participants eligible for inclusion.&#xD;
        Recruitment of healthy participants will also occur by leveraging the services of the CHOP&#xD;
        Recruitment Enhancement Core (REC), Pediatric Research Consortium (PeRC) and the RecruitMe&#xD;
        tool provided by the Clinical Trials Office at CUMC. Healthy adult controls will be&#xD;
        recruited from patients who receive outpatient care within the Penn Primary Care Networks,&#xD;
        Penn employees and students, an extensive database of individuals who have participated in&#xD;
        prior research studies at Penn and through local advertising on the Penn campus.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for participants with glomerular disease:&#xD;
&#xD;
          1. CureGN participant or CureGN Eligible&#xD;
&#xD;
             CureGN eligible is defined as having a diagnosis of Glomerulonephropathy (GN).&#xD;
             Patients would otherwise be enrolled in be in CureGN study, except for lacking a minor&#xD;
             entry criteria, such as:&#xD;
&#xD;
               1. First diagnostic kidney biopsy within 5 years of CureGN study enrollment&#xD;
&#xD;
               2. Access to first kidney biopsy report and/or slides or not being interested in&#xD;
                  study participation.&#xD;
&#xD;
          2. Males or females 5 to 55 years (premenopausal for women)&#xD;
&#xD;
          3. Females must have a negative urine/serum pregnancy test&#xD;
&#xD;
          4. Stable doses of nutritional vitamin D or active vitamin D therapy for at least 3&#xD;
             months before enrollment ((if on either form of Vitamin D)&#xD;
&#xD;
          5. Consent/Parental/guardian permission (informed consent) and if appropriate, child&#xD;
             assent&#xD;
&#xD;
        Inclusion Criteria for healthy reference participants&#xD;
&#xD;
          1. Males or females 5 to 55 years of age (premenopausal for women)&#xD;
&#xD;
          2. Females must have a negative urine/serum pregnancy test&#xD;
&#xD;
          3. Consent/Parental/guardian permission (informed consent) and if appropriate, child&#xD;
             assent&#xD;
&#xD;
        Exclusion Criteria for all participants&#xD;
&#xD;
          1. Chronic Dialysis&#xD;
&#xD;
          2. Solid organ transplantation&#xD;
&#xD;
          3. Lower extremity amputations or non-ambulatory&#xD;
&#xD;
          4. Malignancy requiring chemotherapy or metastatic to bone&#xD;
&#xD;
          5. Metabolic bone disease (e.g., Paget's disease, primary hyperparathyroidism)&#xD;
&#xD;
          6. Endocrinopathy (current hyperthyroidism or untreated hypothyroidism, Cushing's&#xD;
             syndrome)&#xD;
&#xD;
          7. Medical diseases (end stage liver disease, heart or lung disease, intestinal&#xD;
             malabsorption)&#xD;
&#xD;
          8. Those treated with bisphosphonates, teriparatide, calcitonin, selective estrogen&#xD;
             receptor modulators, estrogen, or phenytoin in the past 12 months&#xD;
&#xD;
          9. Previous bilateral wrist and tibia fractures&#xD;
&#xD;
         10. Pregnant or lactating females&#xD;
&#xD;
         11. Parents/guardians or participants who, in the opinion of the Investigator, may be&#xD;
             non-compliant with study schedules or procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas L. Nickolas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria A. Aponte</last_name>
    <phone>(212) 342-4678</phone>
    <email>maa2308@cumc.columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas L. Nickolas, MD</last_name>
    <phone>(212) 305-3273</phone>
    <email>tln2001@cumc.columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria A. Aponte</last_name>
      <phone>212-342-4678</phone>
      <email>maa2308@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas L. Nickolas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Doherty</last_name>
      <phone>267-600-6233</phone>
      <email>dohertye@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Michelle R. Denburg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. Lancet. 2017 Mar 25;389(10075):1238-1252. doi: 10.1016/S0140-6736(16)32064-5. Epub 2016 Nov 23. Review.</citation>
    <PMID>27887750</PMID>
  </reference>
  <reference>
    <citation>Floege J, Amann K. Primary glomerulonephritides. Lancet. 2016 May 14;387(10032):2036-48. doi: 10.1016/S0140-6736(16)00272-5. Epub 2016 Feb 25. Review.</citation>
    <PMID>26921911</PMID>
  </reference>
  <reference>
    <citation>Saran R, Robinson B, Abbott KC, Agodoa LY, Albertus P, Ayanian J, Balkrishnan R, Bragg-Gresham J, Cao J, Chen JL, Cope E, Dharmarajan S, Dietrich X, Eckard A, Eggers PW, Gaber C, Gillen D, Gipson D, Gu H, Hailpern SM, Hall YN, Han Y, He K, Hebert H, Helmuth M, Herman W, Heung M, Hutton D, Jacobsen SJ, Ji N, Jin Y, Kalantar-Zadeh K, Kapke A, Katz R, Kovesdy CP, Kurtz V, Lavalee D, Li Y, Lu Y, McCullough K, Molnar MZ, Montez-Rath M, Morgenstern H, Mu Q, Mukhopadhyay P, Nallamothu B, Nguyen DV, Norris KC, O'Hare AM, Obi Y, Pearson J, Pisoni R, Plattner B, Port FK, Potukuchi P, Rao P, Ratkowiak K, Ravel V, Ray D, Rhee CM, Schaubel DE, Selewski DT, Shaw S, Shi J, Shieu M, Sim JJ, Song P, Soohoo M, Steffick D, Streja E, Tamura MK, Tentori F, Tilea A, Tong L, Turf M, Wang D, Wang M, Woodside K, Wyncott A, Xin X, Zang W, Zepel L, Zhang S, Zho H, Hirth RA, Shahinian V. US Renal Data System 2016 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2017 Mar;69(3 Suppl 1):A7-A8. doi: 10.1053/j.ajkd.2016.12.004. Review. Erratum in: Am J Kidney Dis. 2017 May;69(5):712.</citation>
    <PMID>28236831</PMID>
  </reference>
  <reference>
    <citation>Clark SL, Denburg MR, Furth SL. Physical activity and screen time in adolescents in the chronic kidney disease in children (CKiD) cohort. Pediatr Nephrol. 2016 May;31(5):801-8. doi: 10.1007/s00467-015-3287-z. Epub 2015 Dec 18.</citation>
    <PMID>26684326</PMID>
  </reference>
  <reference>
    <citation>Denburg MR, Kumar J, Jemielita T, Brooks ER, Skversky A, Portale AA, Salusky IB, Warady BA, Furth SL, Leonard MB. Fracture Burden and Risk Factors in Childhood CKD: Results from the CKiD Cohort Study. J Am Soc Nephrol. 2016 Feb;27(2):543-50. doi: 10.1681/ASN.2015020152. Epub 2015 Jul 2.</citation>
    <PMID>26139439</PMID>
  </reference>
  <reference>
    <citation>Phan V, Blydt-Hansen T, Feber J, Alos N, Arora S, Atkinson S, Bell L, Clarson C, Couch R, Cummings EA, Filler G, Grant RM, Grimmer J, Hebert D, Lentle B, Ma J, Matzinger M, Midgley J, Pinsk M, Rodd C, Shenouda N, Stein R, Stephure D, Taback S, Williams K, Rauch F, Siminoski K, Ward LM; Canadian STOPP Consortium. Skeletal findings in the first 12 months following initiation of glucocorticoid therapy for pediatric nephrotic syndrome. Osteoporos Int. 2014 Feb;25(2):627-37. doi: 10.1007/s00198-013-2466-7. Epub 2013 Aug 16.</citation>
    <PMID>23948876</PMID>
  </reference>
  <reference>
    <citation>Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, Wong C, Stehman-Breen C. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 2000 Jul;58(1):396-9.</citation>
    <PMID>10886587</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 24, 2020</study_first_submitted>
  <study_first_submitted_qc>August 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2020</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney Disease</keyword>
  <keyword>Bone Fracture</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Fractures, Bone</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Only investigators and study team members that have completed appropriate institutional review board (IRB) training/approval are eligible to collect and work on information collected from this study.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

